Myeloma Minute..IMF

[annie]

comparto con vosotros " Myeloma Minute" de la IMF, publicado a finales de septiembre
Cita:
"WHAT'S NEWS

Going to ASH? Pre-register now for "Myeloma Questions and Controversies: New Developments in 2011 That Impact Diagnosis, Prognosis, and Treatment
In this interactive, case-based didactic program, expert faculty members discuss evolving data in the optimal management of patients with multiple myeloma--from diagnosis to treatment. Audience participation includes both polling questions and question and answer sessions after each presentation.

December 9, 2011
San Diego Marriott Marquis
Marriott Hall
333 West Harbor Drive
San Diego, CA 92101
619-234-1500

Register online »

Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma
ONYX announced that it has completed the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) under the accelerated approval process for carfilzomib, a next generation proteasome inhibitor, for the potential treatment of patients with relapsed and refractory multiple myeloma. In addition, Onyx has requested priority review of the application, which reduces the time the FDA takes to review a new drug application. (from Onyx)
http://www.onyx-pharm.com/news/onyx-pha ... le-myeloma

Save the Date!! The 5th Annual Comedy Celebration benefiting the Peter Boyle Memorial Fund
Ray Romano hosts Tom Arnold, Dom Irrera, Garry Shandling, Darrell Hammond, Colin Quinn, Fred Willard, and Doris Roberts on Saturday, November 5, 2011 at 6:00pm at the The Wilshire Ebell Theatre & Club in Los Angeles, California
http://myeloma.org/ArticlePage.action?t ... cleId=3469

Researchers Use New Tool To Counter Multiple Myeloma Drug Resistance
"Acquired drug resistance" (ADR) is a major problem encountered in treating some forms of cancer. The ability to monitor the proteins involved in drug resistance has been a hurdle facing cancer researchers. However, a team of researchers at Moffitt Cancer Center, and colleagues, are pioneering promising research utilizing a monitoring technology that could provide a better understanding of ADR and assist in clinical decision-making for developing individualized patient treatments for multiple myeloma. (from Newswise)
http://www.newswise.com/articles/moffit ... resistance
Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90
Apigenin, a common flavonoid, has been reported to suppress proliferation in a wide variety of solid tumors and hematological cancers; however its mechanism is not well understood and its effect on multiple myeloma cells has not been determined. (from Interactive Web)
http://7thspace.com/headlines/392650/ap ... hsp90.html
MorphoSys Doses First Patient in Phase 1/2a Clinical Trial for MOR202 Program in Multiple Myeloma
MorphoSys AG announced today that the first patient in a Phase 1/2a clinical trial of its cancer antibody MOR202 has been dosed. MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target which is highly expressed on multiple myeloma tumor cells and certain leukemias. The phase 1/2a, open-label, multi-centre, dose-escalation study will evaluate the safety and preliminary efficacy of MOR202 in patients with relapsed or refractory multiple myeloma. (from Reuters)
http://www.reuters.com/article/2011/09/ ... UG20110901
Firefighters responding to 9/11 at increased cancer risk
According to research published in the Lancet medical journal, firefighters exposed to toxic dust and fumes clogging the air after the World Trade Center towers collapsed 10 years ago are more likely to develop cancer. The increase occurred during the first seven years after 9/11. (from CNN)
http://edition.cnn.com/2011/HEALTH/09/0 ... rs.cancer/

Novel approach scores first success against elusive cancer gene
Dana-Farber Cancer Institute scientists have successfully disrupted the function of a cancer gene involved in the formation of most human tumors by tampering with the gene's "on" switch and growth signals, rather than targeting the gene itself. The results, achieved in multiple myeloma cells, offer a promising strategy for treating not only myeloma but also many other cancer types driven by the gene MYC, the study authors say. Their findings are being published by the journal Cell on its website Sept. 1 and in its Sept. 16 print edition. (from HealthCanal.com)
http://www.healthcanal.com/cancers/2029 ... -gene.html

Audio posted for the 9/8/11 teleconference: The Importance of Clinical Trial Participation
Listen to Dr. Durie review the ASPIRE trial, a Phase 3 study evaluating carfilzomib in combination with Revlimid and low dose dexamethasone vs. Revdex alone.
http://myeloma.org/ArticlePage.action?t ... 12&aTab=-1
Win a Dream Vacation to Costa Rica!
Help the IMF reach its goal of $200,000 for our Research, Education, Support and Advocacy Programs by participating in Myeloma 200 - Closer to a Cure! and be entered into a drawing for a trip for two for 7 days and 6 nights to the beautiful Four Seasons Costa Rica, including airfare and a $400 gift certificate toward spa treatments.
THE IMF IS BLOGGING AND TWEETING!
https://online.myeloma.org/netcommunity/myeloma200

* Dr. Durie's Blogs:
o 9/11 and Myeloma
http://myeloma.org/MtEntryPage.action?s ... eloma.html
o Early Access to Carfilzomib for Eligible Patients
http://myeloma.org/MtEntryPage.action?s ... ients.html
o China: the new frontier in the search for a cure for myeloma
http://myeloma.org/MtEntryPage.action?s ... eloma.html

* Follow the IMF on Twitter
o @BrianDurieMD
http://twitter.com/#!/BrianDurieMD
o @IMF Comedy
http://twitter.com/#!/IMFComedy
o @IMFMyeloma
http://twitter.com/#!/IMFMyeloma


*

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
van de Donk NW, Kamps S, Mutis T, Lokhorst HM†*
Leukemia (Aug 2011)
http://www.nature.com/leu/journal/vaop/ ... 1214a.html
*

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma
Siegel D†*, Jagannath S†*, Vesole DH†*, Borello I, Mazumder A†, Mitsiades C, Goddard J, Dunbar J, Normant E, Adams J, Grayzel D, Anderson KC†*, Richardson P†*
Leukemia and Lymphoma (Aug 2011)
http://www.docguide.com/phase-1-study-i ... tip?tsid=5
*

Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey
Chan V, Song K, Mang O, Ip DK, Au WY
Leukemia and Lymphoma (Aug 2011)
http://www.ncbi.nlm.nih.gov/pubmed/21851219
*

Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome
Nivison-Smith I, Dodds AJ, Doocey R, Ganly P, Gibson J†*, Ma DD, Simpson JM, Szer J, Bradstock KF
Leukemia and Lymphoma 52 (9), 1727-35 (Sep 2011)
http://www.docguide.com/allogeneic-hema ... era?tsid=5
*

Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma
Keating GM
Drugs 71 (12), 1623-47 (Aug 2011)
http://www.ncbi.nlm.nih.gov/pubmed/21861545
*

Myeloma of the central nervous system: report of a single center case series
Vermeiren P, Vantilborgh A, Offner F
Acta Clinica Belgica 66 (3), 205-8 (2011 May-Jun)
http://www.docguide.com//node/1373439
*

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA†*, Jackson GH, Davies FE†*, Morgan GJ†*
Leukemia (Aug 2011)
http://www.ncbi.nlm.nih.gov/pubmed/21836613
*

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
Shaji K. Kumar†, Hajime Uno, Susanna J. Jacobus, Scott A. Van Wier, Greg J. Ahmann, Kimberly J. Henderson, Natalie S. Callander, Jessica L. Haug, David S. Siegel†*, Philip R. Greipp†, Rafael Fonseca†*, and S. Vincent Rajkumar*
Blood published 22 August 2011, 10.1182/blood-2011-03-342089
http://bloodjournal.hematologylibrary.o ... ct?papetoc
*

Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, Laura A. Bruins, Jessica E. Schmidt, Scott Van Wier, Xiu-Bao Chang, Chad C. Bjorklund, Rafael Fonseca†*, P. Leif Bergsagel†*, Robert Z. Orlowski†, and A. Keith Stewart†*
Blood published 22 August 2011, 10.1182/blood-2011-05-356063
http://bloodjournal.hematologylibrary.o ... ct?papetoc
*

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau†, Herve Avet-Loiseau, Thierry Facon†, Michel Attal†*, Mourad Tiab, Cyrille Hulin, Chantal Doyen, Laurent Garderet, Edouard Randriamalala, Carla Araujo, Gerard Lepeu, Gerald Marit, Denis Caillot, Martine Escoffre, Bruno Lioure, Lotfi Benboubker, Brigitte Pegourie, Brigitte Kolb, Anne Marie Stoppa, Jean-Gabriel Fuzibet, Olivier Decaux, Mamoun Dib, Christian Berthou, Carine Chaleteix, Catherine Sebban, Catherine Traulle, Jean Fontan, Marc Wetterwald, Pascal Lenain, Claire Mathiot, and Jean-Luc Harousseau
Blood published 17 August 2011, 10.1182/blood-2011-05-355081
http://bloodjournal.hematologylibrary.o ... ct?papetoc
*

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
Antonio Palumbo†*, Sara Bringhen, Heinz Ludwig†*, Meletios A. Dimopoulos†*, JoanBlade†*, Maria V. Mateos†, Laura Rosinol†, Mario Boccadoro†*, Michele Cavo†, Henk Lokhorst†*, Sonja Zweegman, Evangelos Terpos†, Faith Davies†*, Christoph Driessen, Peter Gimsing, Martin Gramatzki, Roman Hajek†*, Hans E. Johnsen†, Fernando Leal Da Costa†, Orhan Sezer†*, Andrew Spencer†*, Meral Beksac†*, Gareth Morgan†*, Hermann Einsele†*, Jesus F. San Miguel†*, and Pieter Sonneveld†*
Blood published 12 August 2011, 10.1182/blood-2011-06-358812
http://bloodjournal.hematologylibrary.o ... ct?papetoc
*

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
Sumit Madan, Martha Q. Lacy†, Angela Dispenzieri†, Morie A. Gertz†*, Francis Buadi, Suzanne R. Hayman, Kristen Detweiler-Short, David Dingli, Steven Zeldenrust, John Lust, Philip R. Greipp†, S. Vincent Rajkumar†*, and Shaji Kumar†
Blood 2011;118 1763-1765
http://bloodjournal.hematologylibrary.o ... tract?etoc

CLINICAL TRIALS

* CARFILZOMIB trials
http://www.clinicaltrials.gov/ct2/resul ... &recr=Open

* REVLIMID® trials
http://www.clinicaltrials.gov/ct2/resul ... &recr=Open

* THALOMID® trials
http://www.clinicaltrials.gov/ct2/resul ... &recr=Open

* VELCADE® trials
http://www.clinicaltrials.gov/ct2/resul ... &recr=Open

* VORINOSTAT trials
http://myeloma.org/IndexPage.action?tab ... goryId=438

* Redirected Auto T Cells for Advanced Myeloma
A Pilot Phase I/II, Dual-Cohort, Two-Site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous Tcells Expressing a High Affinity TCR Specific for MAGE-A3/6 or NY-ESO-1 Administered Post ASCT in Patients With Advanced Myeloma
http://www.cancertrialshelp.org/trialch ... tails.aspx

* A Phase II Study of AZD6244 in Multiple Myeloma patients with relapsed/refractory disease who have had two or more prior therapies
The purpose of this study is to find out what effects, good and/or bad, AZD6244 has on participants and their multiple myeloma. In some types of cancer such as myeloma, a protein called MEK is overactive.
http://clinicaltrials.gov/ct2/show/NCT01085214

* Natural History of MGUS and Smoldering Myeloma
The purpose of this study is to discover risk factors that may cause MGUS and SMM to progress to multiple myeloma. Individuals need to be at least 18 years of age who have been diagnosed with either MGUS or SMM but do not have multiple myeloma.
http://clinicaltrials.gov/ct2/show/NCT01109407

* ASPIRE: Phase III study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) vs lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma
The purpose of this study is to compare progression-free survival in subjects with relapsed multiple myeloma who are receiving CRd vs subjects receiving Rd in a randomized multicenter setting.
http://myeloma.org/IndexPage.action?tab ... goryId=438

If you would like more information about any clinical trial, you can call the IMF Hotline at 800-452-CURE. The Myeloma Matrix has a current list of all myeloma trials from pre-clinical to recently FDA approved. If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find EmergingMed, with whom the IMF has entered into a partnership to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute (NCI). To see the summaries of newsworthy clinical trial results, visit the National Cancer Institute Multiple Myeloma Trial Results.
UPCOMING SEMINARS AND CLINICAL CONFERENCES
Note: Some of the international seminar cities have been set, but the venues and agendas are still in the works. Check back often if you are interested in attending, as we post the sites and speakers as they are confirmed.

* Seminario Interattivo Medici, Pazienti e Famiglie
Roma, Italia
30 settembre 2011

* Raleigh-Durham Regional Community Workshop
Chapel Hill, North Carolina
October 30, 2011



* Boca Raton Patient & Family Seminar
Boca Raton, Florida
February 3-4, 2012


Fin de la cita
Un abrazo

[annie]

Os recuerdo que podeis traducir estos articulos, empleando este link.
http://translate.google.es/
un abrazo

[fercu]

Temas muy completos.
Gracias por el aporte.
Chao: fercu y mary